Intervention Review

Ziprasidone for schizophrenia and severe mental illness

  1. Anne-Marie Bagnall1,*,
  2. Jos Kleijnen2,
  3. Maria Leitner3,
  4. Ruth Lewis4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 23 OCT 2000

Assessed as up-to-date: 30 AUG 2000

DOI: 10.1002/14651858.CD001945

How to Cite

Bagnall AM, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001945. DOI: 10.1002/14651858.CD001945.

Author Information

  1. 1

    Leeds Metropolitan University, Faculty of Health, Leeds, UK

  2. 2

    York, UK

  3. 3

    University of Liverpool, Faculty of Medicine, Liverpool, UK

  4. 4

    Cardiff University, Department of Primary Care and Public Health, Wrexham, UK

*Anne-Marie Bagnall, Faculty of Health, Leeds Metropolitan University, Calverley Street, Leeds, LS1 3HE, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 23 OCT 2000


Options for accessing this content:

  • If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
  • Login via other institutional login options
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens


Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.